Segmented Linear Mixed Model Analysis Reveals Association of the APOEɛ4 Allele with Faster Rate of Alzheimer's Disease Dementia Progression.

Journal of Alzheimer's Disease : JAD
X Richard ChenAlzheimer’s Disease Neuroimaging Initiative

Abstract

APOEɛ4 allele carriers present with an increased risk for late-onset Alzheimer's disease (AD), show cognitive symptoms at an earlier age, and are more likely to transition from mild cognitive impairment (MCI) to dementia but despite this, it remains unclear whether or not the ɛ4 allele controls the rate of disease progression. To determine the effects of the ɛ4 allele on rates of cognitive decline and brain atrophy during MCI and dementia stages of AD. A segmented linear mixed model was chosen for longitudinal modeling of cognitive and brain volumetric data of 73 ɛ3/ɛ3, 99 ɛ3/ɛ4, and 39 ɛ4/ɛ4 Alzheimer's Disease Neuroimaging Initiative participants who transitioned during the study from MCI to AD dementia. ɛ4 carriers showed faster decline on MMSE, ADAS-11, CDR-SB, and MoCA scales, with the last two measures showing significant ɛ4 allele-dose effects after dementia transition but not during MCI. The ɛ4 effect was more prevalent in younger participants and in females. ɛ4 carriers also demonstrated faster rates of atrophy of the whole brain, the hippocampus, the entorhinal cortex, the middle temporal gyrus, and expansion of the ventricles after transitioning to dementia but not during MCI. Possession of the ɛ4 allele is associate...Continue Reading

References

Jan 1, 1991·Acta Neuropathologica·H Braak, E Braak
Dec 1, 1996·Journal of Neurology, Neurosurgery, and Psychiatry·C HolmesS Lovestone
Jun 15, 1999·Journal of Neurology·A J SlooterC M van Duijn
Dec 22, 1999·Neurology·M R FarlowB Gulanski
Jun 20, 2000·Neurobiology of Aging·H AkiyamaT Wyss-Coray
Oct 12, 2000·Proceedings of the National Academy of Sciences of the United States of America·P M GreenwoodR Parasuraman
Mar 20, 2001·Current Psychiatry Reports·J W Ashford, F A Schmitt
Nov 24, 2004·Neurology·M R FarlowH C Charles
Apr 9, 2005·Journal of the American Geriatrics Society·Ziad S NasreddineHoward Chertkow
Jun 16, 2005·Archives of Neurology·Adam FleisherUNKNOWN Alzheimer's Disease Cooperative Study
Dec 25, 2007·Neurobiology of Aging·Michael P VitekCarol A Colton
Aug 13, 2008·Archives of Neurology·Sid E O'BryantUNKNOWN Texas Alzheimer's Research Consortium
Jan 24, 2009·Proceedings of the National Academy of Sciences of the United States of America·Federica AgostaMaria Luisa Gorno-Tempini
Apr 2, 2009·Psychological Medicine·A E van der VliesW M van der Flier
Jul 17, 2009·The New England Journal of Medicine·Richard J CaselliEric M Reiman
May 6, 2010·Journal of Alzheimer's Disease : JAD·Jose Viña, Ana Lloret
May 11, 2010·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Michael W WeinerUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jul 1, 2011·Science Translational Medicine·Joseph M CastellanoDavid M Holtzman
Oct 27, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Tadafumi HashimotoBradley T Hyman
Jul 6, 2013·AJNR. American Journal of Neuroradiology·D HollandUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jul 31, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Yu-Ling ChangUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Mar 25, 2016·Journal of Neurology, Neurosurgery, and Psychiatry·Jinping WangAndrew Satlin
Mar 31, 2016·EMBO Molecular Medicine·Dennis J Selkoe, John Hardy
Apr 2, 2016·Current Alzheimer Research·Amanda M Di BattistaG William Rebeck
Sep 2, 2016·Nature·Jeff SevignyAlfred Sandrock
Dec 10, 2016·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Michael W WeinerUNKNOWN Alzheimer's Disease Neuroimaging Initiative

❮ Previous
Next ❯

Citations

Sep 28, 2021·Acta Neuropathologica Communications·Joanna E PankiewiczMartin J Sadowski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.